EDWARDS LIFESCIENCES ENTERS INTO ACCELERATED SHARE REPURCHASE AGREEMENT

Exhibit 99.1

Xxxxxxx Lifesciences Corporation Xxx Xxxxxxx Xxx • Irvine, CA USA • 92614 Phone: 000.000.0000 • Fax: 000.000.0000 xxx.xxxxxxx.xxx

FOR IMMEDIATE RELEASE

Media Contact: Xxxxx Xxxx, 000-000-0000

Investor Contact: Xxxxx X. Xxxxxxxx, 000-000-0000

XXXXXXX LIFESCIENCES ENTERS INTO

ACCELERATED SHARE REPURCHASE AGREEMENT

Irvine, CA, May 1, 2018 – Xxxxxxx Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, announced today that it entered into an accelerated share repurchase (ASR) agreement to repurchase an aggregate of $400 million of Xxxxxxx’ common stock. Under the terms of this ASR agreement, Xxxxxxx will receive approximately 2.5 million shares in May 2018. The final number of shares to be repurchased will be based on the volume weighted average share price during the term of the agreement.

As of March 31, 2018, the company had approximately $1.3 billion authorization remaining on its share repurchase program approved by the Board of Directors.

About Xxxxxxx Lifesciences

Xxxxxxx Lifesciences, based in Irvine, Calif., is the global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring. Driven by a passion to help patients, the company collaborates with the world’s leading clinicians and researchers to address unmet healthcare needs, working to improve patient outcomes and enhance lives. For more information, visit xxx.Xxxxxxx.xxx and follow us on Twitter @EdwardsLifesci.

# # #

Xxxxxxx is a trademark of Xxxxxxx Lifesciences Corporation. Xxxxxxx Lifesciences and the stylized E logo are trademarks of Xxxxxxx Lifesciences Corporation and are registered in the United States Patent and Trademark Office.